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Abstract 
This paper describes a voluntary anonymous survey to investigate the 
seroprevalence of Hepatitis C (HCV) in children in Glasgow, UK attending a Dental 
Hospital and the proportion of HCV positive mothers who have a child who is HCV 
seropositive. The study was undertaken among children and accompanying parents 
and household contacts attending a general anaesthetic assessment clinic at 
Glasgow Dental Hospital and School.  
Children were asked to provide an oral fluid specimen for HCV testing. 
Accompanying adults were asked to provide demographic data on the child and 
information on familial risk factors for HCV infection using a standardised 
questionnaire. Birth mothers were also asked to provide an oral fluid specimen. 
Specimens and questionnaires were linked by a unique anonymous study number. 
Between June 2009 and December 2011, samples were collected from 2141 
children and 1698 mothers. None of the samples from the children were HCV 
seropositive but 16 (0.9%, 95% CI 0.6% to 1.5%) of the specimens from mothers 
were HCV antibody positive.  
In summary, the prevalence of HCV seropositivity in the birth mothers of the children 
was similar to that estimated  in the general population served by the hospital and 
showed no evidence of mother-to-child transmission of HCV. 
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Introduction 
HCV is a major public health problem in Scotland, with an estimated 38,000 
individuals chronically infected with the virus (1). It is believed that around half of 
those infected are undiagnosed (approximately 18,000) and the majority have a 
history of injecting drug use (2).  
A significant number of studies of the prevalence of HCV infection have been 
completed in a variety of international locations, including both endemic and non-
endemic areas (3-20). There are few data on the prevalence of HCV in children and, 
with the exception of a pilot study in Glasgow (21), no prevalence surveys have been 
conducted exclusively among children in the UK. Many of the data on childhood 
prevalence globally have been derived from sub-analyses of larger cross-sectional 
surveys of the general population (3-5, 7-9, 12), though some have focused on 
children (6, 10, 13-20). There is worldwide geographic variation in the prevalence of 
HCV infection in children. With the exception of surveys of children from African 
countries (8, 9, 17, 18) the reported prevalence of HCV in children is usually very low 
and frequently less than 1% (6, 10, 13-16, 19, 20).  
Perinatal (vertical) transmission is widely believed to be the most common source of 
HCV infection in children (22). The risk of transmission from an HCV RNA positive 
mother at birth is estimated at 5%, increasing with increasing viral load, and almost 
entirely confined to those with viral loads of ≥106/ml (23-25). Transmission has also 
been shown to be associated with maternal history of injecting drug use (26). 
Although paternal HCV infection has been reported as a risk factor for perinatal HCV 
infection, it is not an independent risk factor, but is dependent on maternal 
intravenous drug use (26).  
There are an estimated 5000 people who inject drugs (PWID) currently in the 
NHSGG&C health board area aged between 15 and 54 years (27) and the 
prevalence of HCV in this population has been reported as 68% (28). While it is 
anticipated that children of current and former PWIDs will be at increased risk of 
HCV infection, little is known about the prevalence of HCV in children in this 
geographical area. A previous pilot study in Glasgow (21), which assessed the 
feasibility and acceptability of recruiting children for an anonymous cross-sectional 
survey of HCV infection using an oral fluid collection device, reported a prevalence of 
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2.9% (2/70, 95%CI: 0.35 – 9.9), which was higher than in the general Scottish 
population, where the prevalence is approximately 1% (1). Although the sample size 
for the study was small, the surprisingly high prevalence rate reported in this study 
underscored the need to investigate HCV prevalence in the paediatric population in 
Scotland. The high prevalence rate was thought likely to reflect the large population 
of current and former injecting drug users who reside in Glasgow and the high level 
of social deprivation of the population who attend the Dental Hospital and School.  
The primary objective of this study was, therefore, to determine the seroprevalence 
of HCV among children in Glasgow. Secondary objectives were to determine the 
association between markers of HCV infection in mothers and children, and to 
identify risk-factors for HCV infection in children. This information is important in 
order to inform whether case finding of children living in households with guardians 
who inject is required, and the treatment, care and support needs for this population, 
which in the USA have been identified as substantial (29). 
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Methods 
Study design 
A cross-sectional survey of children, and when possible their birth mothers, resident 
in Glasgow and the West of Scotland, recruited from the child patient population 
attending the General Anaesthetic (GA) Assessment Clinic at the Glasgow Dental 
Hospital and School, for assessment prior to dental extraction.  
 
Ethical approval 
Approval for the study was granted by the West Glasgow 2 Research Ethics 
Committee. 
 
Recruitment of participants 
Prior to each child’s attendance at the clinic, an invitation letter and information 
leaflet was sent to parents / guardians along with the child’s appointment card, in 
order to inform them of the study. Upon attendance, a research nurse approached 
parents / guardians, explained the study and procedure in detail and invited them to 
provide informed written consent for the child to participate in the survey. Children 
aged over seven years were also asked to provide written consent and children aged 
less than seven years were asked to assent verbally to participate. The investigator 
employed a variety of communication strategies, including play, to communicate with 
the children, in particular pre-school children.  
Children were excluded from the study if they were accompanied by a guardian who 
did not have parental rights to consent for them to participate; were not attending the 
clinic for assessment; or were aged less than 3 years and more than 14 years. 
 
Data collection and handling  
The Research Nurse interviewed the parents / guardians to collect anonymous 
demographic and risk factor data for HCV infection for the child and mothers using a 
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standardised questionnaire. Age, gender and ethnic background of participants were 
recorded, together with post-code data to allow a deprivation category to be 
assigned to each participant. In addition, for each child, data were recorded on 
recognised risk factors for HCV infection (blood transfusion, organ transplant, 
surgery, tattoos and piercings and overseas medical treatment); co-habitation with a 
parent or other household member who was a current or former injecting drug user; 
co-habitation with a parent or other household member who was HCV positive; risk 
factors for intra-familial horizontal transmission (including sharing toothbrushes); risk 
factors for vertical transmission (maternal HCV infection, maternal HCV / HIV co-
infection, mode of delivery at birth) and maternal country of birth. The maternal risk 
factors for infection collected were intravenous drug use, history of blood transfusion 
or organ transplant and overseas medical treatment. Household contacts were 
identified using the definition used in the 2001 Scottish census, as “a group of people 
(not necessarily related) living at the same address with common housekeeping, 
sharing either a living room or sitting room, or at least one meal a day”. 
Data collected on those who declined to participate were the age and gender of the 
child, the relationship of the accompanying adult to the child and the reason for non-
consent, to allow assessment of any response bias. 
Data were entered on a daily basis into a password protected Microsoft Access 
database on a secure password protected computer. Post-code data were 
automatically converted to a social deprivation category using the Scottish Index of 
Multiple Deprivation (SIMD), then redacted on the questionnaire and rendered 
unreadable, in order to protect patient confidentiality. All data were held in 
accordance with the Caldicott guidelines 
(http://www.connectingforhealth.nhs.uk/systemsandservices/infogov/caldicott ) and 
the Data Protection Act 1998 (http://www.legislation.gov.uk/ukpga/1998/29/contents). 
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Saliva specimen collection 
Saliva specimens were collected from both children and birth mothers using the 
OraSure collection device (Epitope Inc, Oregon, USA). Participants were asked to 
insert the device into their mouth between the lower cheek and gum and retain it for 
two minutes. Specimens were placed into a labelled vial and stored at -40oC before 
transport to the West of Scotland Specialist Virology Centre (WSSVC) for testing. 
Specimens from a child and adult were linked to the questionnaire data using a 
unique anonymous number. 
 
Laboratory testing 
Oral fluid specimens were tested for HCV antibodies using a modified protocol for 
the Ortho HCV 3.0 SAVe ELISA (Product number 940982, Ortho Diagnostics 
Amersham). The sensitivity and specificity of this assay are 92% and 99% 
respectively (30). All reactive samples were repeated using the same assay and 
weakly reactive samples were further tested using modified protocols of the 
recombinant immunoblot assay (RIBA). The virology laboratory held a secure 
Microsoft Access database containing the unique anonymous study number, date of 
HCV test, sample viability and HCV antibody test result, which was merged on a 
quarterly basis with the main study database. 
 
Data analysis  
All statistical analyses were carried out using SPSS version 17 and STATA version 
9.2. Results were presented as numbers and percentages. Representativeness of 
the study population was assessed using chi-square test comparing the gender, age, 
ethnicity and relationship with accompanying adult of the participants and non-
participants. HCV prevalence is presented with the 95% confidence limits (Cl) 
calculated using the Wilson method for small n. Factors associated with maternal 
HCV infection were determined using univariable logistic regression analysis. 
Associations were expressed as odds ratio (OR) together with their 95% CI. 
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Multivariable logistic regression analysis was not performed due to the collinearity of 
the predictor variables 
 
Results 
Of the 3,111 children attending the General Anaesthetic (GA) Assessment Clinic at 
Glasgow Dental Hospital and School during the recruitment period, 259 did not meet 
the inclusion criteria and were excluded. Of those eligible to participate (n=2852), 
2141 consented to participate in the survey giving an overall participation rate of 
75% (Figure 1). Compared to participants, non-participants tended to be younger (P= 
<0.001) and non-Caucasian (P= <0.001) (Table 1). 
Of the 2141 children participating, 1141 (53%) were female and 1333 (62%) aged 
between 3-6 years. Fifty nine percent of children participating were resident in areas 
of Glasgow considered to be the most deprived (SIMD quintile 4 and 5). Sixty seven 
children (3.1%) reportedly lived with someone who had a history of drug use; of 
these 31 (46.3%) also lived with someone who was HCV positive. One hundred and 
three (4.8%) children were of South Asian ethnicity. Ten (9.7%) lived with, and 12 
(11.6%) had contact with, someone who was HCV positive. Twenty four children 
(1.15%) were living with someone who was HCV positive but did not live with 
someone who had a history of drug use or were of South Asian ethnicity.  All children 
provided an oral fluid specimen for HCV antibody testing, and zero (0%, 95% CI 0% 
to 0.2%) were antibody positive 
Oral fluid specimens were obtained from the majority of birth mothers accompanying 
their children (n= 1698, 99.3%). Sixteen birth mothers (0.9%, 95% CI 0.6% to 1.5%) 
were HCV antibody positive. Half of the HCV antibody positive mothers were aware 
of their HCV positive status at the time of interview. Factors associated with maternal 
HCV antibody were South Asia place of birth (P = 0.03) and history of injecting drug 
use (P<0.001). In addition to South Asia place of birth (P=0.001), receipt of medical 
treatment overseas (P= 0.007) was also associated with maternal HCV antibody 
when mothers with a history of injecting drug use were excluded from the analysis 
(Table 2).
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Figure 1: Recruitment and hepatitis C testing of participants in the hepatitis C prevalence survey of  
children at Glasgow Dental Hospital and School, August 2009 to December 2011.  
    Number attending clinic 
N=3111 
       
  
 
   Total Excluded = 259 (8.3%) 
of 3111 children attending                                                                                                                                    
Not age eligible = 87                 
Accompanying adult did not  
have parental rights = 172                                                                     
  
          
  
      Number eligible to 
participate 
 N = 2852 (91.7%) 
  
          
                    
          Total declined to participate 
= 711 (24.9%) of 2852 eligible                                                                                                                                                                
Unable to participate = 29                 
Declined to participate* = 670                             
Language difficulties / no 
interpreter = 15                                             
  
                    
                    
      Consented to participate            
N = 2141 (75.1%) 
            
                    
                    
  Attended with birth 
mother N = 1700 
(79.4%) 
                
                  
                  
                    
  Mother Tested for 
HCV N = 1698 
(79.3%) 
        Child Tested for 
HCV             
N=2141 (100.0%) 
      
                    
                    
  Mother HCV Positive 
N = 16 (0.9 %)** 
        Child HCV Positive    
N = 0 (0 .0%) 
      
                    
* Reasons for not being able to take part include physical and learning disabilities.     
** 10 of 12 mothers (83.3%) who had confirmatory RIBA tests tested RIBA positive       
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Table 1: Comparison of characteristics of participants and non-participants in the 
eligible study population (n= 2855) 
Characteristic 
Non participants 
n = 711 
% (n) 
Participants 
n = 2141 
% (n) 
p-
value1 
Sex       
Female 49.6 (353) 46.7 (1000)   
Male 50.4 (358) 53.3 (1141) NS 
        
Age-group (years)       
3-6 72.7 (517) 62.3 (1333)    
7-10 23.6 (168) 29.8 (638)    
11-14 3.6 (26) 7.9 (170)  <0.001 
        
Ethnicity       
Caucasian 79.7 (567) 92.0 (1970)   
South Asian 11.0 (78) 4.8 (103)   
Other 9.2 (66) 3.2 (68) <0.001 
        
Relationship of accompanying adult       
Mother 83.1 (591) 79.4 (1700)   
Father 16.5 (117) 18.4 (395)  0.004 
Guardian lives with child 0.4 (3) 2.12 (46)   
 
 
1chi-square test. NS is not significant at 5% level
11 
 
Table 2 Factors associated with HCV Ab prevalence among mothers of children attending Glasgow Dental Hospital, 2009 to 2011 
  Prevalence of HCV Antibodies 
(All) 
Univariate 
Analysis  
All 
 Prevalence of HCV 
Antibodies (excluding 
PWID) 
  Univariate Analysis2 
Excluding PWID 
 Total 
N 
n % of N 95% CI   OR 95
% 
CI 
 P Total N n % of N 95% CI  OR 95
% 
CI 
 P 
All 1698 16 0.9 0.6 1.5      1684 10 0.6 0.3 1.0     
Deprivation1  (NR=1)                    
Most deprived 1026 13 1.3 0.7 2.2  1.0*    1017 10 0.9 0.5 1.8 1.0*    
Less deprived 671 3 0.4 0.2 1.3  0.4 0.1 1.2 0.1 666 0 0.0 0.0 0.5 0.2 0.0 1.3 NS 
Maternal place of birth                    
UK 1608 13 0.8 0.5 1.4  1.0*    1595 7 0.4 0.2 0.9 1.0*    
South Asia 28 2 7.1 2.0 22.6  9.5 2.0 44.0 0.004 28 2 7.1 2.0 22.6 17.5 3.5 88.1 0.001 
Other 62 1 1.6 0.3 8.6  4.7 0.3 15.6 NS 61 1 1.6 0.3 8.7 3.8 0.5 31.2 0.221 
Previous blood transfusion (NR=13)                    
No 1515 14 0.9 0.6 1.6  1.0*    1504 10 0.7 0.4 1.2 1.0*    
Yes 170 2 1.2 0.3 4.2  1.3 0.3 5.7 NS 167 0 0 0 2.2 1.0 0.1 7.9 NS 
Overseas medical treatment (NR=3)                    
No 1589 13 0.8 0.5 1.4  1.0*    1577 7 0.4 0.2 0.9 1.0*    
Yes 106 3 2.8 1.0 8.2  3.5 1.0 12.6 0.05 104 3 2.9 1.0 8.1 6.7 1.7   
 
26.1 0.007 
History of injecting drug use (NR=16)                    
No 1684 10 0.6 0.3 1.1  1.0*             
Yes 14 6 42.9 21.4 67.8  125
.2 
36.8 428.
5 
<.001          
 
1 most deprived = simdquintile 1-3; less deprived = simdquintile 4 & 5; 2  Sampling zeros were managed by adding one to each zero cell.  
                                                                                                                                                                                                                                                                                                       
NR= non response 
*Baseline 
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Discussion 
There are no data on HCV infection in the child population of the UK, although the prevalence 
is expected to be much lower than in the adult population. In Scotland, approximately 0.8% of 
the population aged 15-59 years had been diagnosed HCV antibody positive by the end of 
2014. The largest proportion of the diagnosed individuals resides in the NHS Greater Glasgow 
and Clyde Board area. Those at greatest risk of infection include past and current people who 
inject drug and individuals of South Asian origin (1, 31). It is therefore possible that children of 
infected women with a history of injecting drugs will be at the greatest risk. Children born to 
migrants from HCV endemic areas may also be at increased risk. 
A high proportion of children attending the general anaesthetic assessment clinic at Glasgow 
Dental Hospital and School come from areas of high social deprivation. They are more likely to 
be from families with a history of injecting drug use and therefore more likely to have a family 
member who is infected with HCV. While the prevalence of HCV antibodies in participants from 
medium to low deprivation areas (SIMD deciles 4-6) was as expected (0.4%), the prevalence 
among those recruited from high deprivation areas (SIMD 1-3) was lower than expected (1.3% 
compared to an anticipated 4%). 
 
The overall HCV antibody prevalence in the mothers recruited to this study is consistent with 
the epidemiology of HCV infection among the general population of Scotland (1). As expected, 
mothers with a history of injecting drug use or those of South Asian origin were significantly 
more likely to be HCV antibody positive. These groups were, however, under-represented, with 
only 1.5% and 0.5% of the final sample reporting to be of South Asian origin or providing a 
history of injecting drug use respectively. The prevalence in both groups was higher than that 
reported previously, but the figures are based on small numbers (28, 31). Given the small 
number of HCV positive mothers in the sample, it is perhaps not surprising that no HCV 
positive children were identified. The prevalence of HCV antibodies in this study was lower 
than that previously reported in a small pilot study undertaken in the same clinic setting (21). 
The pilot study did not collect any demographic or risk information on the participants or their 
mothers, and the reasons for the observed difference are unknown. 
 
There are a number of possible explanations for the small proportion of mothers in the final 
sample with a recognised risk for HCV infection. First, self-exclusion of mothers who had a 
history of injecting drug use is likely, as 32% of adults accompanying the child to the clinic 
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indicated that the reason for non-participation was their unwillingness to disclose risk factors; it 
is not known whether these individuals were more likely to be infected. Self-exclusion of 
mothers who knew that they or their children were already infected with HCV is also possible. 
Second, non-disclosure of a previous risk for HCV is also plausible. Indeed, only half of the 
HCV antibody positive mothers disclosed a recognised risk factor(s) at the point of recruitment. 
Third, the under-representation of those from S. Asia in the final sample may have been a 
result of fewer children being accompanied by their birth mother when compared with the 
Caucasian children (60% versus 86%) or as a consequence of a language barrier, though 
fewer than 2% of those eligible to participate specifically mentioned this as a reason for non-
participation. Finally, the study protocol excluded any child who attended with an adult who did 
not have parental rights to consent to the child’s participation. Certain adults who are ‘in loco 
parentis’ such as foster parents or social workers may accompany children who are more likely 
to come from areas of deprivation or to have parents with a history of drug use. Under-
recruitment of such children may have led to an underestimation of HCV prevalence in our 
child population. However, our data indicate that only 17 children were accompanied by a 
social worker or a foster carer. 
 
As the mothers at greatest risk of HCV infection are under-represented, there is the possibility 
that HCV antibody positive children may have been missed. If we assume that the participants 
are similar in all other respects, we might estimate (by applying the prevalences found) that we 
missed four HCV antibody positive mothers who were born outwith the UK; four HCV antibody 
positive mothers who had received treatment outwith the UK (most likely these being the same 
individuals) and 22 HCV antibody positive mothers who had a history of injecting drug use. 
Therefore, overall there may have been 42 HCV infected mothers in the population eligible to 
participate. If we assume 75% chronicity and 5% HCV transmission rate we might have 
expected one HCV antibody positive child to be identified. 
 
The strengths of this study were our large sample size of healthy children with paired maternal 
and child specimens for HCV antibody testing linked to risk information for HCV infection from 
both mother and child. In addition, our study was conducted in a clinic that treats a large 
number of children from areas of high level social deprivation that include a large population of 
current and former injecting drug users.  
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There were three key limitations to the study. First, there was the risk that mothers who 
believed they were at risk of HCV infection chose not to take part. We know this was an issue 
in this voluntary study and it is a pertinent reminder of the challenges of voluntary surveys of 
children where the maternal risk can be stigmatising and fear of social care interventions can 
prevent participation and/or disclosure. Secondly, while the decision to collect a non invasive 
saliva specimen was taken to encourage participation of children, the sensitivity of the assay 
we used was only 92% and we were unable to establish chronic infection. Finally, we have 
assumed that the HCV-seropositive women were positive at the time of birth of the child, but 
this may not have been the case, since infection may have occurred after the pregnancy. 
 
In conclusion, despite the limitations alluded to above, this study showed that the prevalence of 
HCV infection in the birth mothers of children attending a General Anaesthetic pre-assessment 
clinic prior to dental extractions was similar to the estimate of infection in the general 
population served, and showed no evidence of mother to child transmission in this small group 
of infected individuals. However, given the introduction of highly effective antiviral treatment for 
hepatitis C, resources should be concentrated on identifying and testing infants born to HCV 
infected women.    
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